Anti-p40 Antibodies Ustekinumab and Briakinumab: Blockade of Interleukin-12 and Interleukin-23 in the Treatment of Psoriasis
The DOI matches its Crossref record.
Abstract
The choice of therapeutic agents for patients with moderate-to-severe psoriasis has expanded significantly in the past decade. With new understanding of the immunologic basis of psoriasis, multiple new potential targets for therapy have been identified. It is likely that a series of new medications to focus on the newly identified pathways is on the horizon. The first pathway targeted by new medications focuses on the p40 subunit that is shared by interleukin (IL)-12 and IL-23. Two human anti-p40 antibodies have been used therapeutically in psoriasis to date, ustekinumab (CNTO-1275, Stelara, Centocor, Horsham, PA) and briakinumab (ABT-874, Abbott, Abbott Park, IL). Ustekinumab was recently approved by the United States Food and Drug Administration, making it the first medication approved in the United States to work by this pathway while briakinumab is currently in phase III clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132448 · Cited by 462
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez-Fariñas, M., Haslett, P. A., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383
Interleukin-23: A key cytokine in inflammatory diseases
Duvallet, E., Semerano, L., Assier, E., Falgarone, G., & Boissier, M.-C. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.577093 · Cited by 282
Update on psoriasis immunopathogenesis and targeted immunotherapy
Mahil, S. K., Capon, F., & Barker, J. N. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-015-0539-8 · Cited by 245
“Further, anti-IL-12/IL-23 and anti-IL-23 agents are highly effective therapeutic agents [98].”
BackgroundAdaptive immunity in atherosclerosis: mechanisms and future therapeutic targets
Lahoute, C., Herbin, O., Mallat, Z., & Tedgui, A. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.62 · Cited by 229
Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics
Schoch, A., Kettenberger, H., Mundigl, O., Winter, G., Engert, J., Heinrich, J., & Emrich, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408766112 · Cited by 202
“Interestingly, ustekinumab has a median terminal half-life of 22 d (26) whereas briakinumab has a terminal half-life of only 8–9 d (25, 27, 28).”
BackgroundCurrent Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163
The problem of choice: current biologic agents and future prospects in RA
Choy, E. H., Kavanaugh, A. F., & Jones, S. A. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.8 · Cited by 141
Antibody variable sequences have a pronounced effect on cellular transport and plasma half-life
Grevys, A., Frick, R., Mester, S., Flem-Karlsen, K., Nilsen, J., Foss, S., Sand, K. M. K., Emrich, T., Fischer, J. A. A., Greiff, V., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103746 · Cited by 51
“Therefore, we conducted a thorough biochemical, cellular, and in vivo analysis of two monoclonal IgG1 antibodies, briakinumab and ustekinumab, that target the same antigen, the p40-subunit of interleukin (IL)-12/23, but that have very distinct plasma half-lives in humans, 9 versus 23 days, respectively (Gandhi et al.,…”
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
Metadata
- Authors
- Gandhi, M., Alwawi, E., & Gordon, K. B.
- Venue
- Seminars in Cutaneous Medicine and Surgery
- Published
- 2010-03
- Volume
- 29
- Issue
- 1
- Pages
- 48-52
- ISSN
- 1085-5629 (ISSN-L)
- OpenAlex
- W2084325957
- Cited by
- 68
- References
- 0
- FWCI
- 3.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.